Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop shows promise for allergy itch

NCT ID NCT04622345

Symptom relief Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested whether VSJ-110 eye drops can reduce itching and redness caused by allergic conjunctivitis (eye allergies). 47 adults received either the active eye drop or a placebo, then were exposed to an allergen. The study measured how much their eyes itched and reddened in the minutes after exposure. Results will show if VSJ-110 works better than placebo for quick symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VSJ-110 ophthalmic solution (eye drops)
What this could lead to
If it works, this could lead to a new eye drop that quickly relieves itching and redness caused by eye allergies.
What could go wrong
This is a small, early-phase trial (47 people) testing a short-term response in a lab setting. Real-world effectiveness and long-term safety are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

47 people

The number who actually took part.

Started

Nov 2020

Finished

Jun 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age of either gender and any race * Able to provide written informed consent and sign the HIPAA form * Willing and able to follow all instructions and attend all study visits Exclusion Criteria: * Able and willing to avoid all disallowed medications during washout and study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic conjunctivitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic conjunctivitis

Contacts and locations

Locations

  • Vanda Investigational Site

    Andover, Massachusetts, 01810, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.